Virpax Pharmaceuticals, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
10-Q: Virpax Pharmaceuticals Reports Q3 2024 Results Amidst Financial Challenges and Strategic Shifts
Virpax Pharmaceuticals' Q3 2024 report reveals ongoing losses, a significant decrease in cash, and strategic changes including a new CEO and cost-cutting measures.
OTC.Pink
10-Q: Virpax Pharmaceuticals Reports Q2 2024 Results Amidst Ongoing Losses and Financial Restructuring
Virpax Pharmaceuticals reported a net loss of $6.7 million for the first half of 2024, alongside significant changes in its board and financial structure.
OTC.Pink
Virpax Pharmaceuticals reported a net loss of $3.2 million for the first quarter of 2024 and faces substantial doubt about its ability to continue as a going concern due to ongoing losses and cash obligations.